Compare Hut 8 Corp (HUT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Recursion Pharmaceuticals Inc — how do they compare? Hut 8 Corp trades at $81.7 (market cap $9.82B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Hut 8 Corp is far larger — about 4.6× Recursion Pharmaceuticals Inc's market cap, and Hut 8 Corp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HUT | RXRX | |
|---|---|---|
Market Cap | $9.82B | $2.14B |
Volume | 10,272,678 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $133.02 | $6.79 |
52-Week Low | $33.76 | $2.84 |
Typical Hold Time | 11 Days | 22 Days |
Enterprise Value | $17.25B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $89.3, down 3.17% today, amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 with a negative net margin, though revenue grew to $235.12 million. Recent news highlights a $1.07 billion credit facility and AI infrastructure deals, fueling optimism. Analyst consensus is strongly bullish with a $156.79 price target.
The outlook balances strong analyst support and AI infrastructure growth potential against persistent losses and high valuation multiples. Key risks include execution on profitability and competitive pressures in the digital infrastructure space.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
